Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
Relzomostat
Cat. No.:
OB0425LY-027
Appearance:
Solid
Purity:
≥95%
Identity:
Confirmed by NMR.
Size:
Add to basket
Product Overview
Description:
Relzomostat is a potent inhibitor of methionine aminopeptidase 2 (MetAP2).
Synonyms:
Relzomostat [INN]; 2081078-92-2; 2,6-Diazaspiro(3.3)heptane-2-carboxylic acid, 6-(2,2-difluoroethyl)-, (3R,4S,5S,6R)-5-Methoxy-4-((2R,3R)-2-methyl-3-(3-methyl-2-buten-1-yl)-2-oxiranyl)-1-oxaspiro(2.5)oct-6-yl ester
CAS No.:
2081078-92-2
Compound CID:
146014918
Formula:
C24H36F2N2O5
Formula Weight:
470.55
Specification
Target:
MetAP
Pathway:
Metabolic enzyme/Protease
Storage:
Storage at -20°C.
Applications:
Relzomostat can be used for research on obesity, type 2 diabetes and other obesity-related diseases.
